Loading
Vaccines and Immunoinformatics Approaches / RNA Interference and Gene Delivery · Journal article
Idosr Journal of Scientific Research · September 7, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review article examining the theoretical promise of mRNA-based vaccines targeting Plasmodium falciparum circumsporozoite protein. The source summarizes preclinical immunological advantages of mRNA platforms (rapid engineering, potent immune induction, scalable manufacturing) and lipid nanoparticle delivery systems, but reports no clinical trial results, efficacy data, or direct evidence of superiority over currently approved vaccines (RTS,S/AS01 and R21/Matrix-M). It identifies mRNA vaccines as a future research direction rather than an established clinical advance.
Narrative review article. Review covering literature on P. falciparum malaria prevention; disease context includes sub-Saharan Africa as a major burden area..
mRNA platforms demonstrated promising preclinical immunogenicity against circumsporozoite protein epitopes and potent humoral and cellular immune induction Lipid nanoparticle delivery systems enhanced antigen expression and promoted balanced adaptive immune responses Currently deployed protein-based platforms RTS,S/AS01 and R21/Matrix-M show only moderate and waning efficacy
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review does not report clinical trial data and should not guide clinical practice decisions. It contextualizes mRNA vaccines as a future research area with theoretical advantages over existing approved vaccines, but evidence remains preclinical and translational; practitioners should await clinical trial results before considering implementation.
This is a narrative review synthesizing preclinical and early-stage evidence for mRNA malaria vaccines; it raises the prospect of mRNA platforms as superior to existing vaccines but does not report clinical trial data, efficacy estimates, or head-to-head comparisons in humans.
As stated by the source record.
This review does not report clinical trial data and should not guide clinical practice decisions. It contextualizes mRNA vaccines as a future research area with theoretical advantages over existing approved vaccines, but evidence remains preclinical and translational; practitioners should await clinical trial results before considering implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Malaria remains a major global health burden, with Plasmodium falciparum responsible for the majority of severe disease and mortality, particularly in sub-Saharan Africa, as consistently reported by the World Health Organization. Although recent vaccine approvals marked significant progress, currently deployed protein-based platforms such as RTS, S/AS01 and R21/Matrix-M demonstrated only moderate and waning efficacy, underscoring the need for innovative strategies. The purpose of this review is to critically evaluate mRNA-based vaccine platforms targeting the circumsporozoite protein of P. falciparum, examining their molecular design, immunological performance, translational potential, and current limitations. This article was developed through a comprehensive narrative synthesis of contemporary literature in molecular vaccinology, malaria immunology, and nucleic acid delivery technologies. Accumulating evidence indicated that mRNA platforms offered rapid antigen engineering, potent humoral and cellular immune induction, and flexible manufacturing scalability, with promising preclinical immunogenicity against circumsporozoite protein epitopes. Lipid nanoparticle delivery systems enhanced antigen expression and promoted balanced adaptive immune responses. Nevertheless, challenges remained regarding durability of protection, cold chain logistics, antigenic diversity, and implementation in endemic regions. mRNAbased circumsporozoite protein vaccines represented a transformative frontier in malaria prevention, warranting intensified translational research and strategic global investment. Keywords: mRNA vaccines, Circumsporozoite protein, Plasmodium falciparum, Malaria immunology, Lipid nanoparticles.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.